Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 565 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Eupraxia Pharmaceuticals Inc.
Market Cap
$266.17M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$262.75M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-5482.65%
5Y Avg
-3802.53%
Market Cap
$261.90M
Net Profit Margin
-3.14%
TTM Avg
-28.33%
3Y Avg
-34.54%
5Y Avg
-25.62%
Market Cap
$260.75M
Net Profit Margin
-8.78%
TTM Avg
-964.82%
3Y Avg
-2640.79%
5Y Avg
-1760.53%
Market Cap
$260.75M
Net Profit Margin
-10994.73%
TTM Avg
-520.92%
3Y Avg
-360.66%
5Y Avg
-288.77%
Market Cap
$260.54M
Net Profit Margin
-249.94%
TTM Avg
-1079.05%
3Y Avg
-1080.63%
5Y Avg
-787.30%
Market Cap
$272.91M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$276.26M
Net Profit Margin
-38.13%
TTM Avg
-18.76%
3Y Avg
-107.01%
5Y Avg
-249.44%
Market Cap
$255.98M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2265.94%
5Y Avg
-2185.44%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $266.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.75M | 0.00% | 0.00% | -5482.65% | -3802.53% |
| Anika Therapeutics, Inc. (ANIK)vs › | $261.90M | -3.14% | -28.33% | -34.54% | -25.62% |
| Century Therapeutics, Inc. (IPSC)vs › | $260.75M | -8.78% | -964.82% | -2640.79% | -1760.53% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $260.75M | -10994.73% | -520.92% | -360.66% | -288.77% |
| AC Immune S.A. (ACIU)vs › | $260.54M | -249.94% | -1079.05% | -1080.63% | -787.30% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aurora Cannabis Inc. (ACB)vs › | $276.26M | -38.13% | -18.76% | -107.01% | -249.44% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $255.98M | 0.00% | 0.00% | -2265.94% | -2185.44% |
| Fate Therapeutics, Inc. (FATE)vs › | $278.58M | -1941.09% | -1708.77% | -990.85% | -815.81% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
